443 related articles for article (PubMed ID: 10028312)
1. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
Federici AB; Mannucci PM
Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
[TBL] [Abstract][Full Text] [Related]
3. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
4. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
[TBL] [Abstract][Full Text] [Related]
7. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
9. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
11. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
13. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
14. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor containing factor VIII concentrates.
Berntorp E
Haemophilia; 1999 May; 5 Suppl 2():60-3. PubMed ID: 23401902
[TBL] [Abstract][Full Text] [Related]
16. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP--a survey of European physicians.
Lusher JM
Haemophilia; 1998; 4 Suppl 3():11-4. PubMed ID: 10028313
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
Castaman G; Federici AB; Rodeghiero F; Mannucci PM
Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
[TBL] [Abstract][Full Text] [Related]
18. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
Foster PA
Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the diagnosis and management of von Willebrand disease in Italy.
Federici AB; Castaman G; Mannucci PM;
Haemophilia; 2002 Sep; 8(5):607-21. PubMed ID: 12199668
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
Lethagen S; Berntorp E; Nilsson IM
Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
